Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03214367 · ClinicalTrials.gov registry record · Phase 3

A Study of LY900014 in Participants With Type 1 Diabetes

A Phase 3 study of Type 1 Diabetes Mellitus, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 3
Development phase
1,392
Enrollment target
20
Study locations

NCT03214367 is a Phase 3 study of Type 1 Diabetes Mellitus that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,392 participants, above the 127-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (996% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03214367, a Phase 3 study of Type 1 Diabetes Mellitus, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 3
Development phase
1,392 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to evaluate the efficacy of the study drug LY900014 compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in adults with type 1 diabetes (T1D).

Conditions Studied

Type 1 Diabetes Mellitus

Interventions

  • DRUG Insulin Glargine
  • DRUG Insulin Degludec
  • DRUG Insulin Lispro
  • DRUG LY900014

Study Locations (20)

California

  • John Muir Physician Network Clinical Research Center - Concord
  • AMCR Institute INC - Escondido
  • Valley Endocrine, Fresno - Fresno
  • Marin Endocrine Associates - Greenbrae
  • Diabetes and Endocrine Associates - La Mesa
  • University Clinical Investigators, Inc. - Tustin
  • Coastal Metabolic Research Centre - Ventura

Florida

  • The Center For Diabetes & Endocrine Care - Fort Lauderdale
  • East Coast Institute For Research - Jacksonville
  • Sun Coast Clinical Research, Inc - New Port Richey
  • Metabolic Research Institute Inc. - West Palm Beach

Georgia

  • Atlanta Diabetes Associates - Atlanta
  • East Coast Institute For Research - Macon
  • Endocrine Research Solutions, Inc. - Roswell

Idaho

  • Northwest Clinical Trials - Boise
  • Rocky Mountain Diabetes and Osteoporosis Center - Idaho Falls

Alabama

  • Internal Medicine Center LLC - Mobile

Colorado

  • Barbara Davis Center for Childhood Diabetes - Aurora

Hawaii

  • East West Medical Institute - Honolulu

Illinois

  • Prairie Education and Research Cooperative - Springfield

Trial Details

FieldValue
Enrollment Target 1,392 participants
Start Date 2017-07-17
Est. Completion 2019-08-22
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03214367

The ClinicalTrials.gov registry entry for NCT03214367 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,392 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 127-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (996% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 4 interventions - of which Insulin Glargine is the first listed.

NCT03214367 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT03214367 about?

NCT03214367 is a clinical study titled "A Study of LY900014 in Participants With Type 1 Diabetes". The main purpose of this study is to evaluate the efficacy of the study drug LY900014 compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in adults with type 1 diabetes (T1D).

What is the current status of trial NCT03214367?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,392 participants. The study started on 2017-07-17. Estimated completion is 2019-08-22.

What conditions does trial NCT03214367 study?

This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.

What interventions are being tested in trial NCT03214367?

The interventions under investigation include: Insulin Glargine (DRUG), Insulin Degludec (DRUG), Insulin Lispro (DRUG), LY900014 (DRUG).

Who is sponsoring clinical trial NCT03214367?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03214367 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 1 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 1 Diabetes Mellitus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.